Replies to post #3323 on Rexahn Pharmaceuticals, Inc. (REXN)

[Papalaka]

Approval is a long way off, upcoming catalysts are from Phase 2 data due mid year for 4 indications. That in and of itself is enough to move the PPS substantially.